Subjective Experience Following Psilocybin

Inclusion Criteria:

* Individuals of all sexes, gender identities, and ethnicities
* Ages 18 to 65 years of age at the time of screening
* Ability to read/write in English
* Agree not to consume psychoactive drugs 24 hours before dosing sessions or consume psychedelics during duration of study participation

Exclusion Criteria:

* Any notable abnormality on electrocardiogram or routine medical blood or urinalysis laboratory tests
* Current psychiatric diagnoses, such as: major depressive disorder, generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive compulsive disorder, moderate to severe substance use disorders, eating disorders, personality disorders, post-traumatic stress disorder
* Lifetime or current psychiatric diagnoses of: psychosis, schizophrenia, bipolar disorder
* Family history: a first- or second degree relative with a history of schizophrenia or other psychotic disorders, bipolar I or II
* Medication: Any medication with the potential to interact with the investigational medicinal products, especially those with serotonergic mechanisms of actions like SSRIs, SNRIs or MAO-Inhibitors as well as other antipsychotics
* Currently pregnancy or nursing, trying to become pregnant, or unwilling to use acceptable method of contraception during the study
* Current or recent (within 12 weeks) participation in a clinical trial involving medication administration
* Cognitive impairment (Folsetin Mini Mental State Exam score \< 24)
* A disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal surgery).
* Suffered a traumatic brain injury with one of the following symptoms Loss of consciousness \>30min Alteration of consciousness/mental state \>24h Post-traumatic amnesia \>1 day Glasgow Coma Scale (best available score in first 24 hours) \<13
* Any other circumstances that, in the opinion of the investigators, compromises participant safety